African Health Sciences
Makerere University Medical School
Vol. 9, No. 1, 2009, pp. 54-56
Bioline Code: hs09010
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 9, No. 1, 2009, pp. 54-56
© Copyright 2009 - Makerere Medical School, Uganda
Severe depression following á-interferon usage in a patient with chronic myeloid leukemia|
Mamman, Aisha I.; Yusuf, A.J.; Aminu, Sm; Sheikh, T.L. & Hassan, Dr A.
Chronic myeloid leukaemia (CML), with a median age of 40 years, is one of the commonest haematological malignancies in Nigeria. Cytoreductive agents, which were hitherto the mainstay of treatment, neither induce cytogenetic nor haematologic remission. Alpha-interferon (á-IFN), an endogenous glycoprotein with cytotoxic and natural killer cell enhancer effects has been found to induce haematologic and cytogenetic remission in patients with CML, but neuro- psychiatric complications of á -interferon (á-IFN) usage were not reported in Nigeria.
To report a case of deliberate self-harm in University Lecturer as a side effect of á-IFN in the treatment of CML
Clinical and laboratory follow up of a patient receiving á-IFN in the management of CML from the time of diagnosis of CML to the point of loss of contact.
Result: Severe depression is a complication that may adversely influence the clinical outcome of á-IFN usage
Although interferon related depression is uncommon, it is suggested that pre-therapy interferon assays and neuro-psychiatric assessment are carried out in prospective users of á-IFN
Chronic myeloid leukaemia, interferon-á, depression